Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$146.7MCash on Hand
CF+ Cash Runway
Follow CLLS by emailGet an email when CLLS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CLLS, unsubscribe in one click. Privacy
📣 What CLLS Says Is Next
first half of 2028 · “Cellectis plans to initiate a Phase 1 IIT in China, with preliminary clinical data expected in the first half of 2028.”
Company press release, Nov 13, 2026 · SEC filing
second half of 2027 · “Cellectis plans to initiate a Phase 1 investigator-initiated trial (IIT) in China with preliminary clinical data expected in the second half of 2027.”
Company press release, Oct 28, 2026 · SEC filing
H1 2028 · “The Company plans to initiate a Phase 1 IIT in China and share the preliminary clinical data from this program in H1 2028.”
Company press release, Sep 14, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Restructuring Cellectis reported Q3 2026 results with $149 million in cash and fixed-term deposits as of September 30, 2026, and said cash should fund operations into H2 2028. Its HEAL-101 preclinical data showed up to 70% APOC3 editing, with first clinical data expected H2 2027. Headcount may fall up to 70%. Form 6-K · SEC filing · Press release
Nov 12, 2026 ·
Earnings Cellectis reported nine-month 2026 revenues of $14,771 thousand, down from $62,552 thousand a year earlier, with research and development expenses rising to $108,797 thousand from $69,081 thousand. Form 6-K · SEC filing · Press release
Nov 9, 2026 ·
Earnings Cellectis will report third quarter 2026 financial results on November 12, 2026 after the U.S. market close, followed by an investor call and webcast on November 13, 2026 at 8:00 a.m. ET. No results are included in this filing. Form 6-K · SEC filing · Press release
Oct 28, 2026 ·
Clinical trial Cellectis presented expanded preclinical data for .HEAL-101, an APOC3 base editor for severe hypertriglyceridemia, at ESGCT. Mean in vivo human APOC3 editing was about 65%, reaching up to 70%, and triglycerides fell 75% ± 11% in a disease model. A Phase 1 trial in China is planned. Form 6-K · SEC filing · Press release
Sep 14, 2026 ·
Restructuring Cellectis said its board approved a shift to an in vivo gene editing company, with preliminary Phase 1 data planned for H2 2027 (.HEAL-101) and H1 2028 (.HEAL-201). It is exiting lasme-cel and eti-cel development and expects cash runway into H2 2028. Form 6-K · SEC filing · Press release
Sep 11, 2026 ·
Cellectis will host a business update conference call and webcast on Monday, September 14, 2026, at 8:00 a.m. ET in English and 9:00 a.m. ET in French. No financial or clinical results were included in the announcement. Form 6-K · SEC filing · Press release
Sep 1, 2026 ·
Cellectis said it will present at several investor conferences, including Wells Fargo on September 10, Baird on September 15 (presentation 12:50 to 1:20 p.m. ET), Barclays on October 6, Stifel on November 10-12, and Jefferies on November 16-19, 2026. Management will be available for investor meetings. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Aug 2027 · Phase 1/2 · Recruiting · Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not CLLS's own candidates): Alemtuzumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
CLLS holds $146.7M in cash and short-term investments and its operations are currently cash-flow neutral or positive.
Dilution pressure:20 · Moderate
No operating cash burn in latest filings
Share count +57% in a year +20
Recent financing filings on SEC EDGAR:
Jul 2, 2025 · Shelf registration, up to $200M · F-3
Share count 71,751,201 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full CLLS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CLLS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.